Karen Campos
Nurse Practitioner · Miami, FLNPI 1437806288
Payments from drug & device makers
Across 253 payments — averaging $23.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$611
- Actelion Pharmaceuticals US, Inc.$556
- Boehringer Ingelheim$512
- Galderma Laboratories, L.p.$343
- Regeneron Healthcare Solutions, Inc.$283
- plus $2K from 20 others
What the payments were for
- Food & beverage$5,86898%
- Education$1082%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 49 | $1,222 |
| AstraZeneca | 33 | $611 |
| Actelion Pharmaceuticals US, Inc. | 13 | $556 |
| Boehringer Ingelheim | 31 | $512 |
| Galderma Laboratories, L.p. | 4 | $343 |
| Regeneron Healthcare Solutions, Inc. | 14 | $283 |
| Sanofi | 11 | $268 |
| Mallinckrodt Hospital Products Inc. | 17 | $261 |
| United Therapeutics Corporation | 11 | $251 |
| Mylan Specialty L.p. | 11 | $234 |
| Baxter Healthcare | 11 | $206 |
| Boston Scientific | 3 | $195 |
| Insmed, Inc. | 8 | $177 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $148 |
| Amgen | 6 | $134 |
| Bayer | 5 | $105 |
| AbbVie | 2 | $100 |
| Grifols USA, LLC | 4 | $81 |
| Electromed, Inc. | 3 | $70 |
| Novartis | 2 | $45 |
| Philips North America LLC | 3 | $44 |
| Medtronic | 1 | $33 |
| Pfizer | 2 | $31 |
| ANI Pharmaceuticals, Inc. | 1 | $28 |
| Inogen, Inc. | 1 | $20 |
| Merck | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,976 in reported general payments places this provider in the 90th percentile of 8,290 nurse practitioner providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $18,480 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $5,218 |
| Montelukast Sodium | 20 | $102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $1,222 | $18,48027 claims |
| Boehringer IngelheimStiolto Respimat | $512 | $5,21811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,290 nurse practitioner providers in Florida.
Other nurse practitioner in Miami
- Margarita FernandezMiami$311K
- Maya BloombergMiami$202K
- Haydee KapinMiami$97K
- Terri PollackMiami$59K
- Amber FederizoMiami$39K
- Patricia Novoa-VogtMiami$35K
- Moriane JosephMiami$23K
- Jolanta BaginskiClearwater$494K
- Adissa PerezWinter Park$370K
- April WessonTampa$342K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.